menu
    • menu
    [{"orgOrder":0,"company":"Alveus Therapeutics","sponsor":"Rhein Healthcare Investors | Andera Partners | Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2026","type":"Series A Financing","leadProduct":"ALV-100","moa":"GIPR | GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Alveus Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Alveus Therapeutics \/ Rhein Healthcare Investors | Andera Partners | Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Alveus Therapeutics \/ Rhein Healthcare Investors | Andera Partners | Omega Funds"},{"orgOrder":0,"company":"Alveus Therapeutics","sponsor":"InterAx Biotech","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Alveus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alveus Therapeutics \/ Alveus Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Alveus Therapeutics \/ Alveus Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Alveus Therapeutics

    Menu

    Alveus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alveus Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Alveus Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Recipient : InterAx Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InterAx, Alveus Partner to Develop Therapeutic Candidate for Metabolic Disease

                            Details : The collaboration aims to develop innovative solutions for metabolic diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 15, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Recipient : InterAx Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alveus Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Alveus Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALV-100

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Rhein Healthcare Investors | Andera Partners | Omega Funds

                            Deal Size : $160.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Alveus Therapeutics Launches with $160M to Advance Next-Gen Therapies for Obesity

                            Details : The Series A financing for ALV-100, a protein targeting GIPR and GLP-1R, will advance research in obesity.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $160.0 million

                            January 08, 2026

                            Lead Product(s) : ALV-100

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Rhein Healthcare Investors | Andera Partners | Omega Funds

                            Deal Size : $160.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.